Table 2.

Iron overload status and univariate outcomes

Outcome	Iron overload defined as LIC >1.8 mg/g		P	Iron overload defined as LIC >5 mg/g		P
	No iron overload, Prob (95% CI)	Iron overload, Prob (95% CI)		No iron overload, Prob (95% CI)	Iron overload, Prob (95% CI)
N	28	60		65	23
Overall survival, 1 y	82% (62-92)	72% (58-81)	.33	74% (61-83)	78% (55-90)	.68
NRM, 1 y*	14% (2%-27%)	13% (5%-22%)	.86	14% (5%-22%)	13% (0%-26%)	.95
Relapse, 1 y*	21% (6%-73%)	23% (13%-34%)	.92	22% (9%-36%)	23% (12%-35%)	.91
Composite end point, 1 y*†	71% (51%-91%)	80% (65%-95%)	.44	72% (53%-91%)	81% (55%-97%)	.94
Serious infections, 1 y*	64% (43%-85%)	73% (59%-88%)	.35	69% (55%-83%)	74% (51%-97%)	.53
Bacterial infections, 1 y*	11% (0%-22%)	13% (5%-22%)	.72	12% (4%-20%)	13% (0%-27%)	.98
Viral infections, 1 y*	57% (37%-77%)	68% (54%-83%)	.27	63% (49%-77%)	70% (46%-93%)	.48
Fungal infections, 1 y*	7% (0%-17%)	12% (4%-20%)	.49	12% (4%-20%)	4% (0%-12%)	.28
Respiratory failure, 1 y*	11% (0%-22%)	18% (9%-27%)	.38	17% (8%-26%)	13% (1%-26%)	.64
Cardiac failure, 1 y*	0%	8% (1%-15%)	.13	6% (1%-12%)	9% (0%-20%)	.53
Renal failure, 1 y*	7% (0%-16%)	10% (3%-17%)	.66	9% (2%-16%)	9% (0%-20%)	.92
Hepatic VOD, 1 y*	4% (1%-8%)	0%	.32	2% (0%-5%)	0%	.74
Acute GVHD, 100 days*	50% (30%-70%)	33% (21%-45%)	.16	42% (29%-54%)	30% (12%-49%)	.44
Chronic GVHD, 1 y*	21% (6%-37%)	17% (7%-26%)	.72	22% (9%-36%)	15% (6%-25%)	.55

Prob, probability.

^*Cumulative incidence estimate.

^†Composite end point includes NRM and complications (serious infections, hepatic VOD, or organ failure).